Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

53.61 -1.12 (-2.05%)
Official Closing Price Updated: 7:00 PM EDT, Jun 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Hims & Hers Health, Inc. Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
28 29 Next >
Hims & Hers ZAVA Acquisition Deal Expands Its Market Opportunity By $52 Billion: Analyst
Hims & Hers is acquiring digital health provider ZAVA to expand into Europe, aiming to boost revenue and international market reach by 2026. 
Via Benzinga
Hims & Hers Health Stock: A Deep Dive Into Analyst Perspectives (10 Ratings)
Via Benzinga
2 Incredible Growth Stocks to Buy Hand Over Fist
Via The Motley Fool
Topics Economy
Exposures Economy
3 Market-Beating Stocks Worth Your Attention
Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three for years on end are almost always the... 
Via StockStory
Market Whales and Their Recent Bets on HIMS Options
Via Benzinga
These stocks are making the most noise in today's session.
Curious about the most active stocks in today's session? Get a glimpse into the stocks that are generating the highest trading volume and capturing market attention. 
Via Chartmill
Check Out What Whales Are Doing With HIMS
Via Benzinga
3 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Unpacking the Latest Options Trading Trends in Hims & Hers Health
Via Benzinga
EXCLUSIVE: May's 20 Most-Searched Tickers On Benzinga Pro — Where Do Apple, Palantir, CoreWeave, Nvidia Rank?
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers. 
Via Benzinga
Hims & Hers To Acquire European Telehealth Brand Zava As It Looks To Expand Globally
The Zava acquisition will enable Hims & Hers to expand its footprint in the U.K. and launch operations in countries such as Germany, France, and Ireland, with other markets expected to follow soon. 
Via Stocktwits
Topics Government
Exposures Political
Hims & Hers Health Stock Is Rising Tuesday: What's Going On?
Hims & Hers Health Inc (NYSE:HIMS) shares are trading higher Tuesday after the company announced an acceleration of its global expansion through the acquisition of ZAVA. 
Via Benzinga
IBD 50's Hims & Hers Health Shoots Higher On A Key Takeover In Europe
The company hopes the deal will help it snag business in the UK, building a similar model to its U.S. platform. 
Via Investor's Business Daily
Topics ETFs
Hims & Hers Announces Plans to Acquire ZAVA, Accelerating Major European Growth Across the UK, Germany, France, and Ireland
From Hims & Hers
Via Business Wire
1 Healthcare Stock Worth Your Attention and 2 to Turn Down
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, and over the past six... 
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
Hims & Hers Faces Retail Skepticism After Layoffs, FDA Ban on Compounded Wegovy
The company said the layoffs were unrelated to the regulatory change. 
Via Stocktwits
Topics Law Enforcement Workforce
Exposures Layoff Legal Product Safety
Novo Nordisk Is Shedding Muscle In The Weight-Loss Brawl With Eli Lilly
Eli Lilly is rapidly encroaching on Novo Nordisk's yearslong lead in GLP-1 drugs. Can Novo hold its tentpole position? 
Via Investor's Business Daily
3 Surprising Stocks That Have More Than Doubled in 2025
Just 14 stocks with market caps above $1 billion have doubled so far this year. They probably aren't the winners you would have predicted. 
Via The Motley Fool
Topics Government
Exposures Political Product Safety
Super Micro Computer, Hims & Hers And Aurora Innovation Are Among Top 10 Large-Cap Losers Last Week (May 19-May 23): Are The Others In Your Portfolio?
Large-cap stocks were the worst performers last week, with declines up to 23%. Reasons include revenue misses, FDA bans, and Uber's stake monetization. 
Via Benzinga
Exposures Product Safety
Benzinga Bulls And Bears: Alphabet, L3Harris, Target — And Latest Tariff News Roils Markets
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. 
Via Benzinga
MarketBeat Week in Review – 05/19 - 05/23
Stocks were moving lower to end the week as tariff concerns returned; however NVIDIA earnings next week may help investors climb the wall of worry 
Via MarketBeat
Topics Artificial Intelligence Bonds Economy
Exposures Artificial Intelligence Debt Markets Interest Rates
8 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Why Hims & Hers Health (HIMS) Stock Is Falling Today
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 6.3% in the afternoon session after Cigna Group's Evernorth division introduced a monthly $200 price cap for weight-loss medications... 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Hims & Hers Introduces 6-Month Wegovy® New Customer Offer
From Hims & Hers
Via Business Wire
Will Hims & Hers Stock Be Okay After UnitedHealth's Sell-Off?
The UnitedHealth stock sell-off might have spooked investors in the medical sector, who are wondering if it will affect shares of Hims & Hers equally. 
Via MarketBeat
Topics Government World Trade
Exposures Political Tariff
Hims & Hers Stock Drops After Evernorth Announces Cheaper Pricing For Weight-Loss Drugs: Retail’s Dull
Truist noted on Thursday that the $200/month price point is "highly attractive compared to other price points in the market," including Hims & Hers' compounded Semaglutide, Wegovy, and Liraglutide... 
Via Stocktwits
Hims & Hers Health Stock Is Tumbling Thursday: What's Happening?
Hims & Hers Health, Inc (NYSE:HIMS) is facing heavy selling pressure Thursday morning as the U.S. Food and Drug Administration's (FDA) ban of compounded drugs with semaglutide takes effect. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Up 157% in 2025, Is It Too Late to Buy Hims & Hers Stock?
Via The Motley Fool
Envista, NeoGenomics, Acadia Healthcare, Astrana Health, and Hims & Hers Health Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after the major pulled back (Nasdaq -1.3%, S&P 500 - 1.4%) as Treasury yields rose, reflecting market anxiety over a draft federal budget that could... 
Via StockStory
Topics Bonds Stocks
Exposures Debt Markets US Equities
< Previous 1 2 3 4 5 6 7 8 9
...
28 29 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.